The study emphasizes gaps in the preeclampsia risk assessment and aspirin consumption

A new study that is the first to be sponsored by Mirvie, which was the first to evaluate the guidelines for the US Preventive Services (USPSTF) for the Preeklampsia risk and the aspirin recipe in a single, nationwide representative, prospective population, while with high risk a sufficient value of the estimation risk of sufficient value on the moderate Risk category for a recognized risk category for the use of nonspirites for asipipilia recommendations.

This cohort study with 5684 participants, which were taken from the prospective study with several central life studies, showed that the guidelines identified almost 89% of pregnancies with increased risk of preeclampsia. 70.3% stood in the category of medium -heavy risk, defined by maternal features and width demographic data, including age, body mass index and breed, while 18.5% were in the category with high risk, including patients with diseases such as chronic hypertension or pre -history of preeclampsia.

The study results suggest that the dark moderation with moderate risk factors can influence the decisions of the clinicians in relation to the daily aspirin recommendations. While 82% of women with a high risk factor were recommended daily, this recommendation only received 37% of people with one or more moderate risk factors. USPSTF, American College of Obstricians and Gynecologists (ACOG) and the Society for Mothers-Fetal Medicine (SMFM) support the instructions to take aspirin into account or recommend with moderate risk factors between 12 and 28 weeks.

“The identification of 9 out of 10 women helps as a risk and that the oversetting teams and pregnant patients do not help,” said Dr. Thomas Mcelrath, Vice President for Clinical Development with Mirvie and a practicing doctor for fetus medicine at Mass General Brigham and the senior author of the study. “Doctors cannot be ready to prescribe aspirin if the majority of their patients fall into the moderate risk category. This is reinforced by less than 25% by compliance with aspirin use of patients in the category of moderate risk category.”

Most pregnant women in the study (70.3%) fell into the medium-heavy risk category using the USPSTF guidelines, but one or more moderate risk factors and no risk factors with high risk were not predicted for the risk of preeclampsia. In people with 2 or moderate risk factors, however, the nulliparity was associated with a slightly increased risk of a preeclampsia without a high risk factor (RR 1,48; 95% CI, 1.35-1.62; p <0.001); There was little or no association with obesity (RR, 1.11; 95% CI, 1.01-1.22; p = 0.048), black breed (RR, 0.95; 95% CI, 0.80-14; p = 0.63) and advanced age (RR, 0.79; 95% CI, 0.65-0.96;

“Preeklampsia quotas in the United States have doubled over the past 15 years and continue to increase in sight without end,” said Kara Boeldt, a survivor and founder and executive director of Endpreeclamps.org. “The introduction of the USPSTF guidelines in 2021 did nothing in the case of Preeklampsia. This important and eye opening study shows that we need new approaches that can predict who is really at risk that the risk of pre -declampsia is really exposed to. A clear, personalized prediction of your preeclamp risk during pregnancy.”

The results of this important study confirm the need for clear, objective measures for predicting preeclamps in order to motivate preventive care. “

Maneesh Jain, CEO and co -founder, Mirvie

“With innovation like EnCompass ™, we can now provide the right patient preventive care at the right time and the influence rates of premature birth.”